61 results
Page 2 of 4
8-K
EX-99.1
ceb950 uiniolgra
10 Aug 20
Recro Reports Second Quarter 2020 Financial Results
7:06am
8-K
EX-2.1
s0c7 cnlm08la
26 Nov 19
Entry into a Material Definitive Agreement
4:54pm
8-K
EX-99.1
1gx dpi6fphbmc2bqhx9
5 Nov 19
Recro Pharma’s Board of Directors Approves Separation of Acute
7:07am
8-K
EX-99.1
fn9cwl4xjn23
5 Apr 19
Cost Associated with Exit or Disposal Activities
4:01pm
8-K
EX-99.1
36kj8s
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
4hvhyz92siqm9ise
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
424B5
834i hfym4f
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
w459 s24rjay4ru4n3
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
7bad 2z3aleognv9
10 Dec 18
Other Events
2:07pm
8-K
EX-99.1
2szj yt8i5x
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
iiqlhjab hhcabrtl5r
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am